Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells

References

• Kornepati AVR, Rogers CM, Sung P, Curiel TJ. The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature. 2023;619(7970):475–486.
   PubMed Web of Science ®Google Scholar
• Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23(2):78–94.
   PubMed Web of Science ®Google Scholar
• Burdak-Rothkamm S, Rothkamm K. DNA damage repair deficiency and synthetic lethality for cancer treatment. Trends Mol Med. 2021;27(1):91–92.
   PubMed Web of Science ®Google Scholar
• Thakur A, Rana M, Mathew J, Nepali S, Pan C-H, Liou JP, Nepali K. Ritika Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship. Bioorg Chem. 2023;141:106893.
   PubMed Web of Science ®Google Scholar
• Zhou J, Du T, Wang X, Yao H, Deng J, Li Y, Chen X, Sheng L, Ji M, Xu B. Discovery of quinazoline-2,4(1H,3H)-dione derivatives containing a piperizinone moiety as potent PARP-1/2 inhibitors─design, synthesis, in vivo antitumor activity, and X-ray crystal structure analysis. J Med Chem. 2023;66(20):14095–14115.
   PubMed Web of Science ®Google Scholar
• Sun Y, Yang H, Yuan J, Wang L, Song S, Chen R, Bao X, Jia L, Yang T, Zhang X, et al. YCH1899, a highly effective phthalazin-1(2H)-one derivative that overcomes resistance to prior PARP inhibitors. J Med Chem. 2023;66(17):12284–12303.
   PubMed Web of Science ®Google Scholar
• Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond parp inhibitors. Cancer Discov. 2017;7(1):20–37.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao Y, Zhang Z, Zhao J, Jia W, Xia C, Wang F, Liu T. Multi-therapies based on PARP inhibition: potential therapeutic approaches for cancer treatment. J Med Chem. 2022;65(24):16099–16127.
   PubMed Web of Science ®Google Scholar
• Myers SH, Ortega JA, Cavalli A. Synthetic lethality through the lens of medicinal chemistry. J Med Chem. 2020;63(23):14151–14183.
   PubMed Web of Science ®Google Scholar
• Köhler A, Schmidt-Zachmann MS, Franke WW. AND-1, a natural chimeric DNA-binding protein, combines an HMG-box with regulatory WD-repeats. J Cell Sci. 1997;110 (Pt 9)(9):1051–1062. :
   PubMedGoogle Scholar
• Zhu W, Ukomadu C, Jha S, Senga T, Dhar SK, Wohlschlegel JA, Nutt LK, Kornbluth S, Dutta A. Mcm10 and And-1/CTF4 recruit DNA polymerase alpha to chromatin for initiation of DNA replication. Genes Dev. 2007;21(18):2288–2299.
   PubMed Web of Science ®Google Scholar
• Jaramillo-Lambert A, Hao J, Xiao H, Li Y, Han Z, Zhu W. Acidic nucleoplasmic DNA-binding protein (And-1) controls chromosome congression by regulating the assembly of centromere protein A (CENP-A) at centromeres. J Biol Chem. 2013;288(3):1480–1488.
   PubMed Web of Science ®Google Scholar
• Li Y, Li Z, Wu R, Han Z, Zhu W. And-1 is required for homologous recombination repair by regulating DNA end resection. Nucleic Acids Res. 2017;45(5):2531–2545.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen JJ. STAT3 plays an important role in DNA replication by turning on WDHD1. Cell Biosci. 2021;11(1):10.
   PubMed Web of Science ®Google Scholar
• Zhao F, Kim W, Kloeber JA, Lou Z. DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells. Exp Mol Med. 2020;52(10):1705–1714.
   PubMed Web of Science ®Google Scholar
• Mozaffari NL, Pagliarulo F, Sartori AA. Human CtIP: A ‘double agent’ in DNA repair and tumorigenesis. Semin Cell Dev Biol. 2021;113:47–56.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu H, Zhang H, Sun C, Hu Z, Tian Q, Peng C, Jiang P, Hua H, Li X, et al. And-1 coordinates with CtIP for efficient homologous recombination and DNA damage checkpoint maintenance. Nucleic Acids Res. 2017;45(5):2516–2530.
   PubMed Web of Science ®Google Scholar
• Ali SR, Jordan M, Nagarajan P, Amit M. Nerve density and neuronal biomarkers in cancer. Cancers (Basel)). 2022;14(19):4817–4832.
   PubMed Web of Science ®Google Scholar
• Sato N, Koinuma J, Fujita M, Hosokawa M, Ito T, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y. Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res. 2010;16(1):226–239.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Q, Gao G, Zhang X, Liu Y, Yuan S, Wang X, Chen JJ. Role of WDHD1 in human papillomavirus-mediated oncogenesis identified by transcriptional profiling of E7-expressing cells. J Virol. 2016;90(13):6071–6084.
   PubMed Web of Science ®Google Scholar
• Wu JY, Lan XL, Yan DM, Fang YY, Peng YX, Liang FF, Jiang L, Huang SN, Mo M, Lin CX, et al. The clinical significance of transcription factor WD repeat and HMG-box DNA binding protein 1 in laryngeal squamous cell carcinoma and its potential molecular mechanism. Pathol Res Pract. 2022;230:153751.
   PubMed Web of Science ®Google Scholar
• Ertay A, Liu H, Liu D, Peng P, Hill C, Xiong H, Hancock D, Yuan X, Przewloka MR, Coldwell M, et al. Correction: WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer. Cell Death Dis. 2021;12(3):269.
   PubMed Web of Science ®Google Scholar
• Wu JY, Niu YT, Huang SN, Tan YM, Yang ZD, Fang YY, Jiang L, Zhang TT, Zeng XF, Peng YX, et al. WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV. FEBS Open Bio. 2023;13(1):102–117.
   PubMed Web of Science ®Google Scholar
• Wu Y, Villa F, Maman J, Lau YH, Dobnikar L, Simon AC, Labib K, Spring DR, Pellegrini L. Targeting the genome-stability Hub Ctf4 by stapled-peptide design. Angew Chem Int Ed Engl. 2017; 56(42):12866–12872.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Y, Sun J, Chen L, Gou W, Chen CW, Zhou Y, Li Z, Chan DW, Huang R, et al. Discovery and characterization of potent And-1 inhibitors for cancer treatment. Clin Transl Med. 2021;11(12):e627.
   PubMed Web of Science ®Google Scholar
• Gou W, Yu X, Wu S, Wu H, Chang H, Chen L, Wei H, Bi C, Ning H, Wu Y, et al. Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer. Cancer Lett. 2022;530:100–109.
   PubMed Web of Science ®Google Scholar
• Whittleston WG. The synthesis of 1, 2, 4-trimethyl-7-isopropylindene. J Am Chem Soc. 1937;59(5):825–826.
   Google Scholar
• Cappellacci L, Barboni G, Palmieri M, Pasqualini M, Grifantini M, Costa B, Martini C, Franchetti P. Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1’-C-methyl adenosine analogues. J Med Chem. 2002;45(6):1196–1202.
   PubMed Web of Science ®Google Scholar
• Gabai VL, Mosina VA, Budagova KR, Kabakov AE. Spontaneous overexpression of heat-shock proteins in Ehrlich ascites carcinoma cells during in vivo growth. Biochem Mol Biol Int. 1995;35(1):95–102.
   PubMedGoogle Scholar
• Xiong J, Barayan R, Louie AV, Lok BH. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: a bench-to-bedside review. Semin Cancer Biol. 2022;86(Pt 2):521–542.
   PubMedGoogle Scholar
• Nambiar DK, Mishra D, Singh RP. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials. Oncol Res. 2023;31(4):405–421.
   PubMed Web of Science ®Google Scholar
• Wang M, Xie C. DNA damage repair and current therapeutic approaches in gastric cancer: a comprehensive review. Front Genet. 2022;13:931866.
   PubMed Web of Science ®Google Scholar